Regeneron Pharmaceuticals Inc $ 598.86 -9.38 (-1.54%)
Volume:
585,692
Avg Vol (1m):
871,873
Market Cap $:
63.71 Bil
Enterprise Value $:
62.79 Bil
P/E (TTM):
23.19
P/B:
7.00
Financial Strength | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.42 | ||
| Equity-to-Asset | 0.63 | ||
| Debt-to-Equity | 0.25 | ||
| Debt-to-EBITDA | 0.63 | ||
| Interest Coverage | 91.44 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 9.74 | ||
| Beneish M-Score | -2.9 | ||
| WACC vs ROIC | |||
Profitability Rank | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 34.64 | ||
| Net Margin % | 37.3 | ||
| ROE % | 28.39 | ||
| ROA % | 20.69 | ||
| ROC (Joel Greenblatt) % | 63.76 | ||
| 3-Year Revenue Growth Rate | 18 | ||
| 3-Year EBITDA Growth Rate | 23.4 | ||
| 3-Year EPS without NRI Growth Rate | 33.8 |
Valuation Rank | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 23.19 | ||
| Forward PE Ratio | 22.27 | ||
| PE Ratio without NRI | 23.19 | ||
| Price-to-Owner-Earnings | 28.43 | ||
| PB Ratio | 7 | ||
| PS Ratio | 8.64 | ||
| Price-to-Free-Cash-Flow | 28.56 | ||
| Price-to-Operating-Cash-Flow | 23.18 | ||
| EV-to-EBIT | 19.17 | ||
| EV-to-EBITDA | 17.95 | ||
| EV-to-Revenue | 7.86 | ||
| PEG Ratio | 0.88 | ||
| Shiller PE Ratio | 66.85 | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.68 | ||
| Days Inventory | 557.1 | ||
| Days Sales Outstanding | 108.62 | ||
| Days Payable | 147.08 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 7.01 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 2.61 | ||
| Price-to-Median-PS-Value | 0.82 | ||
| Price-to-Peter-Lynch-Fair-Value | 0.99 | ||
| Price-to-Graham-Number | 2.69 | ||
| Earnings Yield (Greenblatt) % | 5.22 | ||
| Forward Rate of Return (Yacktman) % | 22.18 |